None listed
Conditions
Interventions
Sponsors
KSO Corporation
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1) Healthy males and females aged 30 to 64 years-old. (2) Subjects whose fasting blood glucose level is 125 mg/dL or under and HbA1c level is 6.4% or under in the screening test. (3) Subjects who can make self-judgment and are voluntarily giving written informed consent.
Exclusion criteria
Exclusion criteria: (1) Subjects who can't stop using medicines, quasi-medicines, supplements and/or functional foods (including Food for Specified Health Uses or Foods with Function Claims) affecting blood glucose or glycation on during test periods. (2) Smokers (3) Subjects who have declared allergic reaction to ingredients of test foods. (4) Subjects who have excessive alcohol intake more than approximately 20 g / day of pure alcohol equivalent or habit of drinking more than 4 days a week. (5) Subjects who can't stop drinking from 2 days before each measurement. (6) Subjects whose daily average sleeping time is less than about 6 hours. (7) Subjects who are shiftworker and/or midnight-shift worker. (8) Subjects who contract or are under treatment for serious diseases (e.g., liver disease, kidney disease, digestive disease, heart disease, respiratory disease, endocrine disease, thyroid disease, adrenal disease and/or metabolic disease). (9) Subjects who are under chronic disease treatment (10) Subjects who have a history and/or a surgical history of digestive disease affecting digestion and absorption. (11) Subjects who are judged as unsuitable for the current study by screening test. (12) Subjects who have been pregnant or subjects who have a plan to become pregnant or breast feed during the study period. (13) Subjects who have donated over 200 mL of blood and/or blood components within the last one month prior to the current study or over 400 mL of blood and/or blood components within the last three months prior to the current study. (14) Subjects who are under treatment for or have a history of drug addiction and/or alcoholism. (15) Subjects who are planning to participate and/or had participated in other clinical studies within the last one month prior to the current study. (16) Subjects who are judged as unsuitable for the current study by the investigator for other reasons.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pentosidine | — |
Secondary
| Measure | Time frame |
|---|---|
| Other glycation markers | — |
Countries
Japan
Contacts
Public ContactYoshika Komori
KSO Corporation Sales department
Outcome results
None listed